|
US5773244A
(en)
|
1993-05-19 |
1998-06-30 |
Regents Of The University Of California |
Methods of making circular RNA
|
|
US5766903A
(en)
|
1995-08-23 |
1998-06-16 |
University Technology Corporation |
Circular RNA and uses thereof
|
|
ES2340499T3
(es)
|
2001-06-05 |
2010-06-04 |
Curevac Gmbh |
Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
|
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
|
DE102005023170A1
(de)
|
2005-05-19 |
2006-11-23 |
Curevac Gmbh |
Optimierte Formulierung für mRNA
|
|
US9012219B2
(en)
|
2005-08-23 |
2015-04-21 |
The Trustees Of The University Of Pennsylvania |
RNA preparations comprising purified modified RNA for reprogramming cells
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
DE102006007433A1
(de)
|
2006-02-17 |
2007-08-23 |
Curevac Gmbh |
Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
|
|
EP2046954A2
(de)
|
2006-07-31 |
2009-04-15 |
Curevac GmbH |
Nukleinsäure der formel (i): gixngn, oder (ii): cixmcn, insbesondere als immunstimulierendes mittel/adjuvans
|
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
|
DE102006061015A1
(de)
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
US20090163705A1
(en)
*
|
2007-05-21 |
2009-06-25 |
Alnylam Pharmaceuticals, Inc. |
Cationic lipids
|
|
CN101977510A
(zh)
|
2007-06-29 |
2011-02-16 |
联邦科学技术研究组织 |
降解毒性化合物的方法
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
EP2535419A3
(de)
|
2007-09-26 |
2013-05-29 |
Intrexon Corporation |
Synthetische 5'UTRs, Expressionsvektoren und Verfahren zur Erhöhung der Transgenexpression
|
|
CN101939428B
(zh)
|
2007-12-11 |
2014-05-07 |
斯克利普斯研究所 |
涉及mRNA翻译增强因子的组合物和方法
|
|
WO2009120247A2
(en)
|
2007-12-27 |
2009-10-01 |
The Ohio State University Research Foundation |
Lipid nanoparticle compositions and methods of making and using the same
|
|
KR101483715B1
(ko)
|
2008-01-31 |
2015-01-19 |
큐어백 게엠바하 |
면역증강제/애주번트인 화학식(NuGlXmGnNv)a를 포함하는 핵산 및 이의 유도체
|
|
AU2009238175C1
(en)
|
2008-04-15 |
2023-11-30 |
Arbutus Biopharma Corporation |
Novel lipid formulations for nucleic acid delivery
|
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
WO2010088927A1
(en)
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
|
US9670487B2
(en)
|
2010-01-22 |
2017-06-06 |
Sirna Therapeutics, Inc. |
Cationic lipids for oligonucleotide delivery
|
|
JP5902616B2
(ja)
|
2010-04-28 |
2016-04-13 |
協和発酵キリン株式会社 |
カチオン性脂質
|
|
EP2387999A1
(de)
|
2010-05-21 |
2011-11-23 |
CureVac GmbH |
Histidin enthaltende Lösung zur Transfektion und/oder Injektion von Nukleinsäuren und deren Verwendungen
|
|
ES2558106T3
(es)
|
2010-07-30 |
2016-02-02 |
Curevac Ag |
Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
EP3202760B1
(de)
|
2011-01-11 |
2019-08-21 |
Alnylam Pharmaceuticals, Inc. |
Pegylierte lipide und deren verwendung zur wirkstofffreisetzung
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
BR112013031553A2
(pt)
|
2011-06-08 |
2020-11-10 |
Shire Human Genetic Therapies, Inc. |
composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
|
|
JP6250543B2
(ja)
|
2011-09-27 |
2017-12-20 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
ジ脂肪族置換peg化脂質
|
|
ES2921724T1
(es)
|
2011-12-07 |
2022-08-31 |
Alnylam Pharmaceuticals Inc |
Lípidos biodegradables para la administración de agentes activos
|
|
JP6305343B2
(ja)
|
2011-12-07 |
2018-04-04 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
活性薬剤の送達のための分岐アルキルおよびシクロアルキルを末端とする生分解性脂質
|
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
EP2623121A1
(de)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmazeutische Zusammensetzung mit einem Polymerträger-Cargo-Komplex und einem Antigen
|
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
|
ES2660129T3
(es)
|
2012-03-27 |
2018-03-20 |
Curevac Ag |
Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP
|
|
MX362981B
(es)
|
2012-03-27 |
2019-02-28 |
Curevac Ag |
Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
|
|
CA2866955A1
(en)
|
2012-03-27 |
2013-10-03 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
|
EP3498267A1
(de)
|
2012-05-25 |
2019-06-19 |
CureVac AG |
Reversible immobilisierung und/oder kontrollierte freisetzung von nucleinsäuren mit nanopartikeln durch (biologisch abbaubare) polymerbeschichtungen
|
|
CA2876155C
(en)
|
2012-06-08 |
2022-12-13 |
Ethris Gmbh |
Pulmonary delivery of mrna to non-lung target cells
|
|
US20150299702A1
(en)
|
2012-11-30 |
2015-10-22 |
Aarhus Universitet |
Circular rna for inhibition of microrna
|
|
MX385338B
(es)
|
2013-02-22 |
2025-03-18 |
CureVac SE |
Combinación de vacunación e inhibición de la trayectoria pd-1.
|
|
US20160145348A1
(en)
|
2013-03-14 |
2016-05-26 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
|
ES2795249T3
(es)
|
2013-03-15 |
2020-11-23 |
Translate Bio Inc |
Mejora sinérgica de la administración de ácidos nucleicos a través de formulaciones mezcladas
|
|
AU2014310930A1
(en)
|
2013-08-21 |
2016-01-21 |
Curevac Ag |
Composition and vaccine for treating prostate cancer
|
|
CN105517569A
(zh)
|
2013-08-21 |
2016-04-20 |
库瑞瓦格股份公司 |
狂犬病疫苗
|
|
SG11201510748PA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Composition and vaccine for treating lung cancer
|
|
CN105451779A
(zh)
|
2013-08-21 |
2016-03-30 |
库瑞瓦格股份公司 |
增加rna编码蛋白表达的方法
|
|
CN105473157A
(zh)
|
2013-08-21 |
2016-04-06 |
库瑞瓦格股份公司 |
组合疫苗
|
|
SG11201510746WA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Respiratory syncytial virus (rsv) vaccine
|
|
WO2015062738A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Gmbh |
Modified rna with decreased immunostimulatory properties
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
AU2014375404C1
(en)
|
2013-12-30 |
2020-11-19 |
CureVac Manufacturing GmbH |
Methods for RNA analysis
|
|
KR102399799B1
(ko)
|
2013-12-30 |
2022-05-18 |
큐어백 아게 |
인공 핵산 분자
|
|
PL3981437T3
(pl)
|
2014-04-23 |
2025-02-24 |
Modernatx, Inc. |
Szczepionki z kwasem nukleinowym
|
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
|
EP3298170B1
(de)
|
2015-05-21 |
2021-12-29 |
Cofactor Genomics, Inc. |
Verfahren zur erzeugung von zirkulärer dna aus zirkulärer rna
|
|
ES3031941T3
(en)
|
2015-05-26 |
2025-07-14 |
Univ Ramot |
Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
|
|
US11000547B2
(en)
|
2015-06-05 |
2021-05-11 |
Dana-Farber Cancer Institute, Inc. |
Compositions related to rna in circularized form
|
|
ES2969082T3
(es)
|
2015-09-17 |
2024-05-16 |
Modernatx Inc |
Compuestos y composiciones para la administración intracelular de agentes terapéuticos
|
|
US10167457B2
(en)
|
2015-10-23 |
2019-01-01 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
|
FI3368507T3
(fi)
|
2015-10-28 |
2023-03-21 |
Acuitas Therapeutics Inc |
Uusia lipidejä ja lipidinanopartikkeliformulaatioita nukleiinihappojen annostelemiseksi
|
|
NZ749593A
(en)
|
2016-06-20 |
2025-10-31 |
Univ Leland Stanford Junior |
Circular rnas and their use in immunomodulation
|
|
JP7086870B2
(ja)
|
2016-06-30 |
2022-06-20 |
アルブータス・バイオファーマー・コーポレイション |
メッセンジャーrnaを送達するための組成物及び方法
|
|
KR20250103795A
(ko)
|
2016-08-03 |
2025-07-07 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
CA3073020A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
EP3707257A4
(de)
|
2017-11-07 |
2021-12-08 |
The University of North Carolina at Chapel Hill |
Verfahren und zusammensetzungen für zirkuläre rna-moleküle
|
|
IL275205B2
(en)
|
2017-12-15 |
2025-03-01 |
Flagship Pioneering Innovations Vi Llc |
Preparations containing circular polyribonucleotides and uses thereof
|
|
AU2019216307A1
(en)
|
2018-01-30 |
2020-07-09 |
Modernatx, Inc. |
Compositions and methods for delivery of agents to immune cells
|
|
EP3802507A1
(de)
|
2018-05-30 |
2021-04-14 |
Translate Bio, Inc. |
Kationische vitamin-lipide
|
|
IL319091A
(en)
|
2018-06-06 |
2025-04-01 |
Massachusetts Inst Technology |
Circular RNA for translation in eukaryotic cells
|
|
GB2596224B
(en)
|
2018-06-19 |
2022-09-07 |
Univ Texas |
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
|
|
US12419965B2
(en)
|
2018-10-01 |
2025-09-23 |
BioNTech SE |
RNA particles comprising polysarcosine
|
|
EP3972653A1
(de)
|
2019-05-22 |
2022-03-30 |
Massachusetts Institute of Technology |
Zirkuläre rns-zusammensetzungen und verfahren
|
|
JP7638972B2
(ja)
|
2019-09-19 |
2025-03-04 |
モデルナティエックス インコーポレイテッド |
治療薬の細胞内送達のための分岐状尾部脂質化合物及び組成物
|
|
CA3155075A1
(en)
|
2019-10-18 |
2021-04-22 |
Michael Mitchell |
Lipid nanoparticles and formulations thereof for car mrna delivery
|
|
TW202204622A
(zh)
|
2020-04-09 |
2022-02-01 |
大陸商蘇州艾博生物科技有限公司 |
針對冠狀病毒之核酸疫苗
|
|
WO2021226597A2
(en)
|
2020-05-08 |
2021-11-11 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
AU2021328980A1
(en)
|
2020-08-20 |
2023-03-09 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
US20230320994A1
(en)
|
2020-08-21 |
2023-10-12 |
The Board Of Regents Of The University Of Texas System |
Functional ionizable phospholipids
|
|
WO2022081694A1
(en)
|
2020-10-13 |
2022-04-21 |
The Trustees Of The University Of Pennsylvania |
In vivo targeting of fibrosis by anti-cd5-targeted fap-car t mrna-lnp
|
|
MX2023004300A
(es)
|
2020-10-13 |
2023-06-22 |
Univ Pennsylvania |
Direccionamiento in vivo de células t para terapia con ácido ribonucleico mensajero (arnm).
|
|
KR20230144574A
(ko)
|
2021-02-09 |
2023-10-16 |
세리나 쎄라퓨틱스, 인코포레이티드 |
폴리옥사졸린-지질 접합체, 및 이를 포함하는 지질 나노입자 및 제약 조성물
|
|
WO2023044343A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
|
JP2024533865A
(ja)
*
|
2021-09-14 |
2024-09-12 |
レナゲード セラピューティクス マネージメント インコーポレイテッド |
環状脂質及びその使用方法
|
|
WO2023141470A2
(en)
|
2022-01-19 |
2023-07-27 |
President And Fellows Of Harvard College |
Immunomodulatory lipids and uses thereof
|
|
CN118871134A
(zh)
|
2022-03-21 |
2024-10-29 |
生物探险有限公司 |
用于增强蛋白质表达的内部核糖体进入位点(IRES)、质粒载体和环状mRNA
|
|
IL315577A
(en)
|
2022-04-05 |
2024-11-01 |
Capstan Therapeutics Inc |
Ionizable cationic lipids and lipid nanoparticles
|
|
CA3255619A1
(en)
*
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
|
|
WO2023240261A1
(en)
*
|
2022-06-10 |
2023-12-14 |
Renagade Therapeutics Management Inc. |
Nucleobase editing system and method of using same for modifying nucleic acid sequences
|
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
|
EP4577520A1
(de)
|
2022-08-26 |
2025-07-02 |
Renagade Therapeutics Management Inc. |
Pegylierte lipidverbindungen und verfahren zur verwendung davon
|